Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Rising Dose Study to Evaluate the Safety, Tolerability and Pharmcokinetics of Escalating Single or Multiple Subcutaneous Doses of TAK-094 in Healthy Lean and Overweight/Obese Otherwise Healthy Subjects
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Apr 2017
Price :
$35
*
At a glance
- Drugs SCO 094 (Primary)
- Indications Diabetes mellitus; Obesity
- Focus Adverse reactions; First in man
- Sponsors Takeda Europe Research & Development Centre
- 06 Apr 2017 New trial record